AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15295955 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg with hydrocodone 5 mg
Number of subjects: 12
Study 15295955 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg alone
Number of subjects: 12
Study 11436942 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ibopamine
Number of subjects: 45
Study 11436942 — intervention group
Group type: COMPARATOR
Intervention: 0.5% dapiprazole
Number of subjects: 45
Study 9626917 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmin
Number of subjects: 17
Study 9626917 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 17
Study 7882821 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 55
Study 7882821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 3346483 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of theophylline in 19.9 mg of ethylenediamine (TE200)
Number of subjects: 11
Study 3346483 — intervention group
Group type: EXPERIMENTAL
Intervention: 351 mg of theophylline in 35 mg of ethylenediamine (TE351)
Number of subjects: 11
Study 3346483 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of theophylline in 300 mg of propxyphylline and 300 mg of diprophylline (TPD)
Number of subjects: 11
Study 3346483 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 11
Study 29270914 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene block (ISB) with 20 mL of levobupivacaine 0.25% and epinephrine 5 µg·mL‐1
Number of subjects: 40
Study 29270914 — intervention group
Group type: COMPARATOR
Intervention: Combined infraclavicular-suprascapular blocks (ICB-SSB) with 20 mL of levobupivacaine 0.25% and 10 mL for SSB
Number of subjects: 40
Study 29270914 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene block (ISB)
Number of subjects: 40
Study 26922549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin treatment (rosuvastatin 20‐40 mg daily)
Number of subjects: 38
Study 26922549 — intervention group
Group type: COMPARATOR
Intervention: Less aggressive statin treatment (simvastatin 20‐40 mg daily)
Number of subjects: 38
Study 24926525 — intervention group
Group type: EXPERIMENTAL
Intervention: Test food (carbohydrate-protein bar with ewe-goat whey)
Number of subjects: 9
Study 24926525 — intervention group
Group type: COMPARATOR
Intervention: Reference food
Number of subjects: 9
Study 22790642 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tadalafil 5 mg (with possible down-titration to 2.5 mg)
Number of subjects: 215
Study 22790642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 21905252 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher scores on scales measuring beliefs that physical activity is beneficial for their disease
Number of subjects: 185
Study 21905252 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher scores on scales measuring motivation for physical activity participation
Number of subjects: 185
Study 21905252 — intervention group
Group type: EXPERIMENTAL
Intervention: Worries about physical activity participation
Number of subjects: 185
Study 18214942 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (IF) 2 mg/kg nebulized by hood three times daily
Number of subjects: 32
Study 18214942 — intervention group
Group type: COMPARATOR
Intervention: Placebo nebulized by hood three times daily
Number of subjects: 32
Study 18214942 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (IF)
Number of subjects: 32
Study 18214942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17064621 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA therapy combined with suture and ligation surgery (SL group, n = 15)
Number of subjects: 30
Study 17064621 — intervention group
Group type: COMPARATOR
Intervention: RFA therapy without suture and ligation surgery (non-SL group, n = 15)
Number of subjects: 30
Study 12488118 — intervention group
Group type: EXPERIMENTAL
Intervention: sleep hygiene + stimulus control
Number of subjects: 55
Study 12488118 — intervention group
Group type: EXPERIMENTAL
Intervention: sleep hygiene + relaxation tape
Number of subjects: 55
Study 12488118 — intervention group
Group type: COMPARATOR
Intervention: waiting-list condition
Number of subjects: 55
Study 10397519 — intervention group
Group type: EXPERIMENTAL
Intervention: One stage full-mouth disinfection (scaling and root planing of 4 quadrants within 24 hours, application of chlorhexidine to all intra-oral niches, rinsing twice daily with 0.2% chlorhexidine solution, and spraying tonsils with 0.2% chlorhexidine spray for 2 months)
Number of subjects: 40
Study 10397519 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (scaling and root planing per quadrant at 2-week intervals and standard oral hygiene instructions)
Number of subjects: 40
Study 8676224 — intervention group
Group type: EXPERIMENTAL
Intervention: LA + V used (group 1)
Number of subjects: 34
Study 8676224 — intervention group
Group type: COMPARATOR
Intervention: LA + V not used (group 2)
Number of subjects: 34
Study 1829902 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg UK 79300
Number of subjects: 14
Study 1829902 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg UK 79300
Number of subjects: 14
Study 1829902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1829902 — intervention group
Group type: EXPERIMENTAL
Intervention: UK 79300 (both dosages)
Number of subjects: 14
Study 6393827 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthelec (transcutaneous cranial electrical stimulation with Limoge currents)
Number of subjects: 20
Study 6393827 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthelec
Number of subjects: 20
Study 6393827 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 20
Study 31615134 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental infant formula (EF)
Number of subjects: 170
Study 31615134 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard infant formula (SF)
Number of subjects: 170
Study 31615134 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants (BF)
Number of subjects: 170
Study 29581034 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care preference (defined as comfort care focusing on quality of life)
Number of subjects: 383
Study 29581034 — intervention group
Group type: COMPARATOR
Intervention: Education level
Number of subjects: 383
Study 26681800 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF (Cisplatin, 5-fluorouracil, Docetaxel)
Number of subjects: 213
Study 26681800 — intervention group
Group type: COMPARATOR
Intervention: PF (Cisplatin, 5-fluorouracil)
Number of subjects: 213
Study 26681800 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF
Number of subjects: 213
Study 26681800 — intervention group
Group type: COMPARATOR
Intervention: PF
Number of subjects: 213
Study 24641687 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 60
Study 24641687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23174049 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (4 U)
Number of subjects: 0
Study 23174049 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA (6 U)
Number of subjects: 0
Study 20537958 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% nifedipine
Number of subjects: 30
Study 20537958 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% nifedipine
Number of subjects: 30
Study 20537958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16965823 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic scoring method using two-channel EOG with amplitude criteria and beta power exclusion
Number of subjects: 265
Study 16965823 — intervention group
Group type: COMPARATOR
Intervention: Standard visual sleep scoring based on EOG, central EEG, and submental EMG
Number of subjects: 265
Study 16340099 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait and step perturbation training
Number of subjects: 18
Study 16340099 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 12359989 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (n = 49)
Number of subjects: 102
Study 12359989 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (n = 53)
Number of subjects: 102
Study 10333643 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological diagnosis of parasitosis using immunoelectrophoresis, Elisa, or Western blot
Number of subjects: 22
Study 10333643 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cell count
Number of subjects: 22
Study 10333643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmission of strongyloidiasis
Number of subjects: 22
Study 7710623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone graft and implant placement in the routine group (20 patients)
Number of subjects: 30
Study 7710623 — intervention group
Group type: COMPARATOR
Intervention: Bone graft and implant placement in the development group (10 patients)
Number of subjects: 30
Study 7710623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone graft and implant placement (both groups)
Number of subjects: 30
Study 2568784 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotrolan
Number of subjects: 0
Study 2568784 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 0
Study 901625 — intervention group
Group type: EXPERIMENTAL
Intervention: BM 15.075 (0.2 g t.i.d.)
Number of subjects: 29
Study 901625 — intervention group
Group type: COMPARATOR
Intervention: Clofibate (0.5 g t.i.d.)
Number of subjects: 29
Study 901625 — intervention group
Group type: EXPERIMENTAL
Intervention: BM 15.075 (0.2 g t.i.d.) and Clofibate (0.5 g t.i.d.)
Number of subjects: 29
Study 30042699 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted treatment (CBT modules focusing on craving, positive expectancy, or impulsivity)
Number of subjects: 379
Study 30042699 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted craving module
Number of subjects: 379
Study 30042699 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 379
Study 27151908 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated delivery system (Navigator Delivery System; Carticept Medical, Inc)
Number of subjects: 40
Study 27151908 — intervention group
Group type: COMPARATOR
Intervention: Standard syringe injection
Number of subjects: 40
Study 27151908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both injection techniques
Number of subjects: 40
Study 27151908 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated delivery system
Number of subjects: 40
Study 25534167 — intervention group
Group type: COMPARATOR
Intervention: 3-dimensional conventional tangential fields (TFs)
Number of subjects: 30
Study 25534167 — intervention group
Group type: COMPARATOR
Intervention: tangential intensity‐modulated therapy (T‐IMRT)
Number of subjects: 30
Study 25534167 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 fields IMRT (4F‐IMRT)
Number of subjects: 30
Study 25534167 — intervention group
Group type: COMPARATOR
Intervention: single arc volumetric‐modulated arc therapy (S‐VMAT)
Number of subjects: 30
Study 23538980 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery program
Number of subjects: 119
Study 20410150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-to-stand training (15 minutes each session, in addition to 30 minutes of general physical therapy three times a week for four weeks)
Number of subjects: 32
Study 18217968 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted surgery (LAS)
Number of subjects: 331
Study 18217968 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (OS)
Number of subjects: 331
Study 16403594 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic knee extensor strength testing at 14 angular velocities in hemiparetic group
Number of subjects: 30
Study 16403594 — intervention group
Group type: COMPARATOR
Intervention: Isokinetic knee extensor strength testing at 14 angular velocities in control group
Number of subjects: 30
Study 16403594 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement error for hemiparetic subjects
Number of subjects: 30
Study 16403594 — intervention group
Group type: COMPARATOR
Intervention: Measurement error for control subjects
Number of subjects: 30
Study 16403594 — intervention group
Group type: EXPERIMENTAL
Intervention: Smallest real difference for hemiparetic subjects
Number of subjects: 30
Study 16403594 — intervention group
Group type: COMPARATOR
Intervention: Smallest real difference for control subjects
Number of subjects: 30
Study 12852929 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10780125 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus contingency management (CM)
Number of subjects: 42
Study 10780125 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 42
Study 10780125 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus CM
Number of subjects: 42
Study 8981202 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg three times daily)
Number of subjects: 44
Study 8981202 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 1736568 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (5 gm)
Number of subjects: 12
Study 1736568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6582585 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined granulocyte and platelet transfusions
Number of subjects: 23
Study 30710467 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk indication from WGS test for Alzheimer's disease
Number of subjects: 909
Study 30710467 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk indication from WGS test for macular degeneration
Number of subjects: 909
Study 30710467 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk indication from WGS test for colon cancer
Number of subjects: 909
Study 29913020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily for 28 days
Number of subjects: 512
Study 29913020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study 29913020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 512
Study 26891839 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (monthly cash transfer conditional on school attendance)
Number of subjects: 2533
Study 26891839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cash transfer)
Number of subjects: 2533
Study 25406046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300 mg/day)
Number of subjects: 37
Study 25406046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 22984272 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX plus IFX
Number of subjects: 40
Study 22984272 — intervention group
Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 40
Study 20515216 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (psychotherapy and pharmacotherapy)
Number of subjects: 504
Study 20515216 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral analysis system of psychotherapy (monotherapy)
Number of subjects: 504
Study 20515216 — intervention group
Group type: COMPARATOR
Intervention: Nefazodone (monotherapy)
Number of subjects: 504
Study 16862549 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy laser intervention applied for 5 days following the start of chemotherapy.
Number of subjects: 60
Study 16862549 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser intervention).
Number of subjects: 60
Study 16862549 — intervention group
Group type: COMPARATOR
Intervention: Low-energy laser intervention and control group comparison.
Number of subjects: 60
Study 16142782 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave electromagnetic field (450 MHz, 0.16 mW/cm2) with 7 Hz modulation frequency
Number of subjects: 10
Study 16142782 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 10
Study 12132977 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg, twice daily for 7 weeks)
Number of subjects: 600
Study 12132977 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 7 weeks)
Number of subjects: 600
Study 11329104 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin pretreatment (group A)
Number of subjects: 56
Study 11329104 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide pretreatment (group B)
Number of subjects: 56
Study 7572947 — intervention group
Group type: EXPERIMENTAL
Intervention: B subunit‐killed whole cell (BS‐WC) or killed whole cell‐only (WC) oral cholera vaccines
Number of subjects: 100
Study 7572947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1981748 — intervention group
Group type: EXPERIMENTAL
Intervention: mifentidine 20 mg at night
Number of subjects: 60
Study 1981748 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 300 mg at night
Number of subjects: 60
Study 6452464 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% topical erythromycin liquid with 1.2% zinc acetate applied twice daily
Number of subjects: 149
Study 6452464 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% topical erythromycin gel with 1.2% zinc octoate applied twice daily
Number of subjects: 149
Study 6452464 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of oral tetracycline twice daily
Number of subjects: 149
Study 6452464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 31159739 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ultrafiltration targeting a haematocrit (HCT) level of 28%
Number of subjects: 60
Study 31159739 — intervention group
Group type: COMPARATOR
Intervention: Non-ultrafiltration (control group)
Number of subjects: 60
Study 31159739 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ultrafiltration
Number of subjects: 60
Study 28416344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunbed intervention (twice weekly exposure for 12 weeks)
Number of subjects: 31
Study 28416344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sunbed exposure)
Number of subjects: 31
Study 25087839 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 25 mg BIW during Cycle 2 after relapse
Number of subjects: 131
Study 25087839 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg BIW for < 12 weeks (or ETN 25 mg BIW for an extra 12 weeks until PGA < 2 was achieved) during Cycle 1
Number of subjects: 131
Study 25087839 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Satisfaction Survey during Cycle 1
Number of subjects: 131
Study 25087839 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Satisfaction Survey during Cycle 2
Number of subjects: 131
Study 23591085 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein drink (HP)
Number of subjects: 10
Study 23591085 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (HC)
Number of subjects: 10
Study 23591085 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 10
Study 21892119 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with PDGF applied weekly to the TM for 6 weeks
Number of subjects: 20
Study 21892119 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied weekly to the TM for 6 weeks
Number of subjects: 20
Study 19487613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (5 clinics)
Number of subjects: 10
Study 19487613 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 clinics)
Number of subjects: 10
Study 17225163 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg)
Number of subjects: 12
Study 17225163 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg/kg)
Number of subjects: 12
Study 17225163 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 12
Study 17225163 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (100 mg)
Number of subjects: 12
Study 17225163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17225163 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 12
Study 15076238 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH) at a dose of 4 mg daily (DD)
Number of subjects: 245
Study 15076238 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH) at a dose of 4 mg on alternate days (AD)
Number of subjects: 245
Study 15076238 — intervention group
Group type: COMPARATOR
Intervention: All groups (DD, AD, PL)
Number of subjects: 245
Study 15076238 — intervention group
Group type: EXPERIMENTAL
Intervention: DD-AD and AD-AD
Number of subjects: 245
Study 11474953 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing with a blow bottle-device
Number of subjects: 98
Study 11474953 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistance-positive expiratory pressure mask (IR-PEP)
Number of subjects: 98
Study 11474953 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing with no mechanical device
Number of subjects: 98
Study 11474953 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 98
Study 9100214 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (HIE: 500 calories 75% VO2 max)
Number of subjects: 8
Study 9100214 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise (LIE: 500 calories 50% VO2 max)
Number of subjects: 8
Study 9100214 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (HIE)
Number of subjects: 8
Study 9100214 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise (LIE)
Number of subjects: 8
Study 9100214 — intervention group
Group type: COMPARATOR
Intervention: Control condition (C) of quiet sitting for 1 hour
Number of subjects: 8
Study 7962341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg)
Number of subjects: 29
Study 7962341 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (2 micrograms/kg)
Number of subjects: 29
Study 7962341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg) plus GHRH (2 micrograms/kg)
Number of subjects: 29